These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 15849052

  • 1. Treatment of pan-drug resistant Acinetobacter baumannii.
    Lee CM, Lim HK, Liu CP, Tseng HK.
    Scand J Infect Dis; 2005; 37(3):195-9. PubMed ID: 15849052
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain.
    Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, Chuang YC.
    J Antimicrob Chemother; 2004 Feb; 53(2):393-5. PubMed ID: 14729739
    [Abstract] [Full Text] [Related]

  • 4. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
    Hiraki Y, Yoshida M, Masuda Y, Inoue D, Tsuji Y, Kamimura H, Karube Y, Takaki K, Kawano F.
    Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME, Fernández-Cuenca F, Docobo-Pérez F, Pachón J, Pascual A.
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [Abstract] [Full Text] [Related]

  • 8. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
    Sayin Kutlu S, Saçar S, Süzer T, Cevahir N, Okke D, Dirgen Caylak S, Turgut H.
    Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical characteristics and therapy of pan-drug resistant Acinetobacter baumannii infection].
    Sun SM, Wang YY, Yao CJ, Li HL, Yu F, Zhang YL, Zhou H, Wang NP.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Oct; 30(10):2351-3, 2359. PubMed ID: 20965844
    [Abstract] [Full Text] [Related]

  • 11. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M, Pujol M, Tubau F, Peña C, Montero A, Domínguez MA, Gudiol F, Ariza J.
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of colistin and ampicillin/sulbactam against Acinetobacter baumannii.
    Punpanich W, Munsrichoom A, Srisarang S, Treeratweeraphong V.
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S95-100. PubMed ID: 22043760
    [Abstract] [Full Text] [Related]

  • 13. Difference in imipenem, meropenem, sulbactam, and colistin nonsusceptibility trends among three phenotypically undifferentiated Acinetobacter baumannii complex in a medical center in Taiwan, 1997-2007.
    Liang-Yu C, Kuo SC, Liu CY, Luo BS, Huang LJ, Lee YT, Chen CP, Chen TL, Fung CP.
    J Microbiol Immunol Infect; 2011 Oct; 44(5):358-63. PubMed ID: 21524973
    [Abstract] [Full Text] [Related]

  • 14. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK, Ying CM, Lee CC, Liu ZK.
    Med Princ Pract; 2005 Oct; 14(5):338-41. PubMed ID: 16103700
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
    Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, Doganay M.
    Chemotherapy; 2013 Oct; 59(5):325-9. PubMed ID: 24525528
    [Abstract] [Full Text] [Related]

  • 16. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin.
    Dueñas Díez AI, Bratos Pérez MA, Eiros Bouza JM, Almaraz Gómez A, Gutiérrez Rodríguez P, Miguel Gómez MA, Orduña Domingo A, Rodríguez-Torres A.
    Int J Antimicrob Agents; 2004 May; 23(5):487-93. PubMed ID: 15120728
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A, Ariza J, Corbella X, Doménech A, Cabellos C, Ayats J, Tubau F, Borraz C, Gudiol F.
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [Abstract] [Full Text] [Related]

  • 19. Emergence of carbapenem resistance in Acinetobacter baumannii in the Czech Republic is associated with the spread of multidrug-resistant strains of European clone II.
    Nemec A, Krízová L, Maixnerová M, Diancourt L, van der Reijden TJ, Brisse S, van den Broek P, Dijkshoorn L.
    J Antimicrob Chemother; 2008 Sep; 62(3):484-9. PubMed ID: 18477708
    [Abstract] [Full Text] [Related]

  • 20. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates.
    Kiratisin P, Apisarnthanarak A, Kaewdaeng S.
    Int J Antimicrob Agents; 2010 Sep; 36(3):243-6. PubMed ID: 20541913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.